Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,198.09 22.12 0.70%
FTSE 100 6,715.80 41.06 0.62%
DAX 9,606.22 62.03 0.65%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Misonix Demonstrates BoneScalpel™ at International Meeting on Advanced Spine Techniques



 Misonix Demonstrates BoneScalpel™ at International Meeting on Advanced Spine
                                  Techniques

BoneScalpel Demonstrated Meaningful Reduction in Blood Loss

PR Newswire

FARMINGDALE, N.Y., July 23, 2013

FARMINGDALE, N.Y., July 23, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announced that it
participated in the 20th International Meeting on Advanced Spine Techniques
(IMAST) in Vancouver, Canada, on July 10-13, 2013.

IMAST was sponsored by the Scoliosis Research Society (SRS), which has gained
recognition as one of the world's premier spine societies, committed to
research and education in the field of spinal deformities. The IMAST meeting
gathered more than 750 of the world's leading spine surgeons, 75% of whom
practice in orthopedics, to discuss, debate and demonstrate innovative
research, most advanced spine technologies and new spine techniques to improve
patient care.

As an industry sponsor of IMAST, Misonix exhibited and demonstrated its
innovative BoneScalpel Ultrasonic Bone Cutting System, which is rapidly
gaining acceptance with spine surgeons worldwide. Consistent with the
scientific theme of the meeting, an abstract titled "Blood Loss Reduced During
Surgical Correction of Adolescent Idiopathic Scoliosis (AIS) with an
Ultrasonic Bone Scalpel" was presented by Dr. Peter O. Newton in the form of
an e-poster. The research concluded that advanced spinal osteotomies over
multiple spinal levels using BoneScalpel resulted in 30-40% reduced blood loss
in patients treated for one of the most common types of spinal deformity,
adolescent idiopathic scoliosis.

"The ultrasonic BoneScalpel allows me to perform precise bone cuts in the
spine safely and efficiently without having to hit on an osteotome close to
the spinal cord, and I was pleasantly surprised by the amount of reduced blood
loss in my spinal deformity surgeries as compared to using traditional
mechanical bone cutting instruments." stated Dr. Newton, an orthopedic spine
surgeon from Rady's Children Hospital in San Diego, CA who specializes in
correcting spinal deformities in pediatric and adolescent patients. "I had
suspected the ultrasonic BoneScalpel contributes to a reduction in bone
bleeding and thus a reduced need for blood transfusions and cell salvage use,
and the results of this study convincingly confirmed this when I compared 20
surgeries with BoneScalpel against two control groups based on my previous
surgical experience."

The BoneScalpel is a novel ultrasonic osteotome used for safe,
tissue-selective bone dissection that encourages en-bloc bone removal and
refined osteotomies while sparing elastic soft tissue structures. Most users
report that the surgical field is relatively bloodless and clean. Loss of
viable bone is minimal and controllable. The BoneScalpel has been used
extensively for bone removal in the cervical, thoracic and lumbar spine,
including deformity surgery.

"We are thrilled to have been part of this meeting of world renowned experts
in advanced spinal surgery," said Michael A. McManus, Jr., President and Chief
Executive Officer of Misonix. "We are privileged to clearly demonstrate the
clinical value associated with the Misonix BoneScalpel as demonstrated with
this important pilot study documenting a significant reduction in blood loss.
Our users have long since reported that the bleeding from cancellous bone is
reduced when making bone incisions with the Misonix BoneScalpel. We are very
pleased with the reduction in intraoperative blood loss associated with the
BoneScalpel and the reduction in the use of expensive sealing agents and
costly blood products such as blood transfusions and intraoperatively obtained
cells savers. The ability to forego the use of these peripheral products
reduces some of the risks to the patient associated with complex spinal
surgeries and results in lower overall treatment costs."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                   Investor Relations Contacts:
Misonix Contact:   Lytham Partners, LLC
Richard Zaremba    Robert Blum, Joe Dorame, Joe Diaz
631-694-9555       602-889-9700
invest@misonix.com mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement